Next-generation CE-SDS: Practical Strategies for Today's Biopharma Lab

CE-SDS (capillary electrophoresis-sodium dodecyl sulfate) remains a cornerstone technique for biotherapeutic characterization. Today's laboratories require greater throughput, flexibility, and analytical performance. Join industry experts as they share real-world experiences implementing next-generation CE-SDS workflows. Explore lessons learned from transitioning established methods to a multi-capillary platform and discover how native fluorescence detection is enhancing AAV capsid protein analysis with improved sensitivity, streamlined workflows, and label-free detection.
- Scale CE-SDS throughput with automation and parallel analysis.
- Streamline CE-SDS method transfer to next-generation platforms.
- Enhance AAV method development with label-free native fluorescence detection.
By attending this webinar you will:
- Gain practical insights into modernizing CE-SDS workflows to improve laboratory productivity, increase throughput, and support growing analytical demands.
- Learn real-world considerations for method transfer and platform adoption.
- Discover how advanced detection approaches such as native fluorescence detection can enhance sensitivity and streamline AAV characterization workflow.
What you need to know
- Start time: 9 am PST (Los Angeles) / 11 am CST (Chicago) / 12 pm EST (New York) / 5 pm GMT (London/Lisbon)
Who should attend
Scientists, lab managers, and technology decision makers who want to increase CE-SDS throughput, streamline method transfer, and apply new detection technologies to support evolving biopharmaceutical modalities.
Speaker: Kimberly Malecka, Ph.D. (Principal Scientist, Roche/Genentech)
Kimberly Malecka, Ph.D., is a Principal Scientist at Roche/Genentech, where she develops and applies capillary electrophoresis methods to support the characterization of AAV therapies. Over the course of her career at Roche/Genentech, Spark Therapeutics, and Janssen Pharmaceuticals, she has helped advance analytical strategies for biologics and gene therapies. Kimberly earned her Ph.D. in Chemistry from the University of Pennsylvania and is passionate about solving complex analytical challenges and sharing practical insights that help scientists accelerate therapeutic development.
Speaker: David Abraham (Laboratory Automation Engineer II, KBI Biopharma)
David Abraham is a Laboratory Automation Engineer II at KBI Biopharma, where he focuses on advancing analytical and process development through automation, digital tools, and continuous improvement. With a background in analytical chemistry and deep experience supporting biologics and biosimilar development, David brings a practical perspective on applying innovative technologies to streamline workflows and enhance scientific outcomes. He holds a Master's degree in Analytical Chemistry from the University of North Carolina at Chapel Hill.
